Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels
Abstract Background We previously reported a Phase 1/2 randomized placebo-controlled trial of systemic administration of bone marrow-derived allogeneic MSCs (remestemcel-L) in COPD. While safety profile was good, no functional efficacy was observed. However, in view of growing recognition of effects...
Main Authors: | Daniel J. Weiss, Karen Segal, Richard Casaburi, Jack Hayes, Donald Tashkin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-021-01734-8 |
Similar Items
-
Serial estimation of serum CRP levels in patients of COPD with acute exacerbation
by: Rajesh Gupta
Published: (2012-01-01) -
Serial estimation of serum CRP levels in patients of COPD with acute exacerbation
by: Rajesh Gupta, et al.
Published: (2013-01-01) -
Mesenchymal stem/stromal cells: the therapeutic effects in animal models of acute pulmonary diseases
by: Sirous Sadeghian Chaleshtori, et al.
Published: (2020-05-01) -
Microalbuminuria and serum CRP: potential biomarkers for cardiovascular risk among stable COPD
by: Ajith Kumar M S, et al.
Published: (2021-01-01) -
Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension
by: Lucas de Mendonça, et al.
Published: (2017-10-01)